Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

China SXT Pharmaceuticals (SXTC) Debt to Equity: 2019-2025

Historic Debt to Equity for China SXT Pharmaceuticals (SXTC) over the last 7 years, with Mar 2025 value amounting to $0.05.

  • China SXT Pharmaceuticals' Debt to Equity fell 98.99% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.45, marking a year-over-year decrease of 31.78%. This contributed to the annual value of $0.05 for FY2025, which is 18.06% up from last year.
  • As of FY2025, China SXT Pharmaceuticals' Debt to Equity stood at $0.05, which was up 18.06% from $0.04 recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Debt to Equity ranged from a high of $0.76 in FY2021 and a low of $0.00 during FY2022.
  • For the 3-year period, China SXT Pharmaceuticals' Debt to Equity averaged around $0.04, with its median value being $0.04 (2024).
  • Per our database at Business Quant, China SXT Pharmaceuticals' Debt to Equity tumbled by 99.91% in 2022 and then soared by 2,697.08% in 2023.
  • Over the past 5 years, China SXT Pharmaceuticals' Debt to Equity (Yearly) stood at $0.76 in 2021, then slumped by 99.91% to $0.00 in 2022, then spiked by 2,697.08% to $0.02 in 2023, then spiked by 125.54% to $0.04 in 2024, then increased by 18.06% to $0.05 in 2025.